Infectious Disease
RSSArticles
-
Community (Herd) Immunity Follows HPV Vaccination
Young women in two primary care clinics in Ohio who were from 13 to 26 years of age with a history of sexual contact were studied using a sequential sampling strategy in a pre-vaccination HPV surveillance study from 2006-2007 and in a postvaccination surveillance study from 2009-2010. Cervicovaginal swabs were genotyped for HPV using PCR amplification techniques. -
Infectious Disease Alert September 2012 Issue in PDF
-
Herpes Zoster Vaccine and the Incidence of Recurrent Herpes Zoster in the Elderly
A common question in clinical practice about the shingles vaccine is whether it is effective in preventing recurrent episodes in patients who have had herpes zoster (HZ). -
Abstract & Commentary: Nasopharyngeal Bacterial Changes with Antimicrobials and Pneumococcal Vaccine
A total of 153 nasopharyngeal swabs were collected as part of a nationwide study in Switzerland from children <2 years of age treated for acute otitis media from 2004-2009. -
Abstract & Commentary: Age of Primary Epstein-Barr Virus Infection Affects Immune Control
Infants in an area with high malaria exposure were infected with EBV at a significantly younger age in infancy, with a much higher incidence of primary EBV infection before 6 months of age. -
Pharmacology Update: Ivermectin Lotion 0.5% (Sklice)
A new topical preparation for the treatment of head lice has been approved by the FDA. Ivermectin is a macrocyclic lactone antibiotic that has been used orally both on and off label for head lice since 2001. -
The Changing Paradigm in Estimating the Risk of Cardiovascular Disease
The lifetime risk of cardiovascular disease is strongly influenced by risk factor burden and may be similar across race and birth cohorts. -
Why All the P Waves?
Scenario: Interpret the lead MCL-1 rhythm strip shown above. Can you explain the irregularity? -
Internal Medicine Alert - Full April 15, 2012 Issue in PDF
-
Advice Ignored on Acute Mountain Sickness
A retrospective survey of 744 Dutch and Belgian travelers who had ventured to 2500 m (8200 feet) or higher revealed that 25% developed acute mountain sickness. Only half of this group had followed pre-travel advice regarding altitude sickness, and few took preventive acetazolamide.